Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years (2023)
- Authors:
- USP affiliated authors: DIAS, MARCIO VINÍCIUS BERTACINE - ICB ; PARISE FILHO, ROBERTO - FCF ; VASSILIADES, SANDRA VALERIA - FCF ; NAVARAUSCKAS, VITOR DE BASTOS - FCF
- Unidades: ICB; FCF
- DOI: 10.33263/BRIAC131.079
- Subjects: TUBERCULOSE; FÁRMACOS; MYCOBACTERIUM TUBERCULOSIS; MICROBIOLOGIA; ANTIBIÓTICOS; INIBIDORES DE ENZIMAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Biointerface Research in Applied Chemistry
- ISSN: 2069-5837
- Volume/Número/Paginação/Ano: v. 13, n. 1 p. 1-20 art. 79, 2023
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
-
ABNT
VASSILIADES, Sandra Valeria et al. Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years. Biointerface Research in Applied Chemistry, v. 13, n. 1 p. 1-20 art. 79, 2023Tradução . . Disponível em: https://doi.org/10.33263/BRIAC131.079. Acesso em: 03 jun. 2024. -
APA
Vassiliades, S. V., Navarausckas, V. B., Dias, M. V. B., & Parise Filho, R. (2023). Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years. Biointerface Research in Applied Chemistry, 13( 1 p. 1-20 art. 79). doi:10.33263/BRIAC131.079 -
NLM
Vassiliades SV, Navarausckas VB, Dias MVB, Parise Filho R. Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years [Internet]. Biointerface Research in Applied Chemistry. 2023 ; 13( 1 p. 1-20 art. 79):[citado 2024 jun. 03 ] Available from: https://doi.org/10.33263/BRIAC131.079 -
Vancouver
Vassiliades SV, Navarausckas VB, Dias MVB, Parise Filho R. Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years [Internet]. Biointerface Research in Applied Chemistry. 2023 ; 13( 1 p. 1-20 art. 79):[citado 2024 jun. 03 ] Available from: https://doi.org/10.33263/BRIAC131.079 - Using a fragment-based approach to identify alternative chemical scaffolds targeting dihydrofolate reductase from Mycobacterium tuberculosis
- Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
- Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity
- Potenciais inibidores de di-idrofolato redutase de Mycobacterium tuberculosis (MtDHFR): Docking molecular, síntese e avaliação enzimática de derivados dos ácidos aminobenzóico e p-aminocinâmico
- Síntese e avaliação biológica de inibidores híbridos com vistas ao tratamento de neoplasias hematológicas
- Folate pathway inhibitors, an underestimated and underexplored molecular target for new anti-tuberculosis agents
- Enzymology of pyran ring A formation in salinomycin biosynthesis
- Structural basis of the selectivity of GenN, an Aminoglycoside N-Methyltransferase involved in gentamicin biosynthesis
- Abordagem estrutural sobre biossínteses, alvos, estratégias de desenvolvimento e resistência a antimicrobianos
- Mycobacterial OtsA structures unveil substrate preference mechanism and allosteric regulation by 2-oxoglutarate and 2-phosphoglycerate
Informações sobre o DOI: 10.33263/BRIAC131.079 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | Mycobacterium tuberculosi... | Direct link | |
| 3070628.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
